FDA Approves Nplate (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia

THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of pediatric...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news